-o-c-o- Is Part Of A Hetero Ring (e.g., Acetonide, Etc.) Patents (Class 514/174)
  • Patent number: 10363238
    Abstract: Implantable medical devices and methods are provided that have one or more statins disposed therein. The medical devices may be implanted at near or in a bone defect to enhance bone growth. In some embodiments, the medical device provided allows for sustain release of the statin and facilitates bone formation and repair of the fracture site.
    Type: Grant
    Filed: April 11, 2016
    Date of Patent: July 30, 2019
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: Ping Li, Jeffrey C. Marx, William F. McKay
  • Patent number: 10105315
    Abstract: The present disclosure provides methods of treating inflammation of the upper gastrointestinal tract, especially the esophagus, by administering an oral corticosteroid. In some cases, the methods include treating eosinophilic esophagitis (EoE) by administering an oral corticosteroid in an induction phase and a maintenance phase to improve peak eosinophilic counts and symptoms. In embodiments, the methods include treating EoE by administering the oral corticosteroid at nighttime and/or while the patient is lying down.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: October 23, 2018
    Assignee: Adare Pharmaceuticals, Inc.
    Inventors: Brian A. Meltzer, Gail M. Comer
  • Patent number: 10105356
    Abstract: Disclosed herein are formulations of pirfenidone or pyridone analog compounds for aerosolization and use of such formulations for aerosol administration of pirfenidone or pyridone analog compounds for the prevention or treatment of various fibrotic and inflammatory diseases, including disease associated with the lung, heart, kidney, liver, eye and central nervous system. In some embodiments, pirfenidone or pyridone analog compound formulations and delivery options described herein allow for efficacious local delivery of pirfenidone or pyridone analog compound. Compositions include all formulations, kits, and device combinations described herein. Methods include inhalation procedures, indications and manufacturing processes for production and use of the compositions described.
    Type: Grant
    Filed: July 24, 2013
    Date of Patent: October 23, 2018
    Assignee: Avalyn Pharma Inc.
    Inventor: Mark William Surber
  • Patent number: 10092552
    Abstract: Disclosed herein are formulations of pirfenidone or pyridone analog compounds for aerosolization and use of such formulations for aerosol administration of pirfenidone or pyridone analog compounds for the prevention or treatment of various fibrotic and inflammatory diseases, including disease associated with the lung, heart, kidney, liver, eye and central nervous system. In some embodiments, pirfenidone or pyridone analog compound formulations and delivery options described herein allow for efficacious local delivery of pirfenidone or pyridone analog compound. Compositions include all formulations, kits, and device combinations described herein. Methods include inhalation procedures, indications and manufacturing processes for production and use of the compositions described.
    Type: Grant
    Filed: January 31, 2012
    Date of Patent: October 9, 2018
    Assignee: AVALYN PHARMA INC.
    Inventor: Mark William Surber
  • Patent number: 9815865
    Abstract: The present invention further provides method of preparing nanocrystals or microcrystals of a hydrophobic therapeutic agent such as fluticasone or triamcinolone, pharmaceutical compositions (e.g., topical or intranasal compositions) thereof and methods for treating and/or preventing the signs and/or symptoms of disorders such as blepharitis, meibomian gland dysfunction or skin inflammation or a respiratory disease (e.g., asthma).
    Type: Grant
    Filed: November 13, 2013
    Date of Patent: November 14, 2017
    Assignee: Nicox Ophthalmics, Inc.
    Inventors: Shikha P. Barman, Ritesh Vasudevan Thekkedath, Koushik Barman, Thomas Cavanagh, Tian Hao, Thomas Bovard Leland
  • Patent number: 9724355
    Abstract: Provided are inclusion complexes comprising fulvestrant and a cyclodextrin. The complexes may be useful for treating various conditions, such as cancer and systemic lupus crythematosus. Also provided are methods of producing the inclusion complexes, methods of using the inclusion complexes in therapy, and kits and unit dosages comprising the complexes.
    Type: Grant
    Filed: September 16, 2011
    Date of Patent: August 8, 2017
    Assignee: SHIMODA BIOTECH (PTY) LTD
    Inventor: Henk Swart
  • Patent number: 9150709
    Abstract: Epoxy resin compositions comprising a) epoxy resins and b) at least one 2-oxo-[1,3]dioxolane derivative of the formula I in which one or two of the radicals R1 to R4 are an electron-withdrawing organic group having 1 to 20 C atoms or an electron-withdrawing heteroatom, and the remaining radicals R1 to R4 are independently of one another an H atom or a hydrocarbon group having 1 to 20 C atoms.
    Type: Grant
    Filed: October 4, 2012
    Date of Patent: October 6, 2015
    Assignee: BASF SE
    Inventors: Rainer Klopsch, Miran Yu
  • Patent number: 9132093
    Abstract: Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.
    Type: Grant
    Filed: August 14, 2012
    Date of Patent: September 15, 2015
    Assignee: COSMO TECHNOLOGIES LIMITED
    Inventors: Roberto Villa, Massimo Pedrani, Mauro Ajani, Lorenzo Fossati
  • Patent number: 9056048
    Abstract: The invention relates to compositions and methods for a one-step synthetic technique for making cationic steroid pharmaceutical compositions for use in treating inflammation and other diseases and disorders.
    Type: Grant
    Filed: October 27, 2008
    Date of Patent: June 16, 2015
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Scott L. Diamond, Jeffrey Alan Gruneich, David E. Fein
  • Publication number: 20150140093
    Abstract: Compositions, methods of making, and methods of using nanoclusters in which the nanoclusters comprise a plurality of nanoparticles having a core of nanoparticles arranged such that the surfaces of the nanoparticles contact adjacent nanoparticles, the nanoparticles comprise an active ingredient, and the nanocluster has a mass median aerodynamic diameter of from about 0.25 ?m to about 20 ?m.
    Type: Application
    Filed: November 6, 2014
    Publication date: May 21, 2015
    Inventors: Cory J. Berkland, Lianjun Shi, Nashwa El Gendy, Carl Plumley, Mark Bailey
  • Publication number: 20150133415
    Abstract: Compositions, and methods of using such compositions, useful for placement, for example injection, into the interior of human or animal eyes are provided. Such compositions include a therapeutic component, such as one or more corticosteroids, a biocompatible polymeric component, and a solvent component. The composition is in a fluid form before placement in the interior of an eye, and becomes less fluid after the composition is placed in the eye to form an extended or delayed release drug delivery element or system. The drug delivery element is formed by the dissipation of the solvent from the composition when the composition is placed in the interior of an eye. One example of a composition includes triamcinolone acetonide as a therapeutic agent. A method of treating an ophthalmic condition, or otherwise improving or enhancing vision of a patient, comprises placing the fluid composition in the interior of the eye. The method may be practiced by injecting the fluid composition into the interior of the eye.
    Type: Application
    Filed: January 16, 2015
    Publication date: May 14, 2015
    Inventor: Scott M. Whitcup
  • Publication number: 20150132284
    Abstract: Provided herein are methods of treating and inducing ulcerative colitis in a subject. Also provided are methods of treating subjects with mild to moderate active ulcerative colitis, including ulcerative proctitis and proctosigmoiditis. Also provided are methods of administering budesonide to a subject to treat ulcerative colitis, including ulcerative proctitis and proctosigmoiditis.
    Type: Application
    Filed: October 30, 2014
    Publication date: May 14, 2015
    Inventors: William P. Forbes, Enoch Bortey, Craig Paterson, Pam Golden
  • Publication number: 20150118296
    Abstract: The present invention relates to controlled release pharmaceutical compositions comprising budesonide. The invention also relates to processes for the preparation of such compositions and using those compositions in the treatment of Inflammatory Bowel Disease and Irritable Bowel Syndrome including mild to moderate ulcerative colitis.
    Type: Application
    Filed: October 22, 2014
    Publication date: April 30, 2015
    Inventors: Shushrut Krishnaji Kulkarni, Ajaykumar Handa, Pushpendra Pratap Singh, Ankur Paresh Shah
  • Publication number: 20150110779
    Abstract: The invention described herein relates to diagnostic and therapeutic methods and compositions useful for predicting the likelihood a cancer patient will experience a gastrointestinal immune-related adverse event (GI-irAE) after administration of a pharmaceutically acceptable amount of an activator of the immune system.
    Type: Application
    Filed: March 15, 2013
    Publication date: April 23, 2015
    Inventors: Vafa Shahabi, Ruiru Ji
  • Patent number: 9012435
    Abstract: The invention relates to nitrooxy derivatives of fluocinolone acetonide, triamcinolone acetonide, betamethasone and beclomethasone, methods for their preparation, pharmaceutical compositions containing these compounds, and methods of using these compounds and compositions for treating diabetic macular edema, diabetic retinopathy, macular degeneration, age-related macular degeneration and other diseases of retina and macula lutea.
    Type: Grant
    Filed: July 19, 2013
    Date of Patent: April 21, 2015
    Assignee: Nicox S.A.
    Inventors: Francesca Benedini, Annalisa Bonfanti, Valerio Chiroli, Rebecca Steele, Ennio Ongini, Stefano Biondi
  • Publication number: 20150105360
    Abstract: This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the prevention or addiction induced anxiety and withdrawal side effects as a therapeutic and in concert with a diagnostic. Such addictions could be, but are not limited to, alcohol, drugs, caffeine, sugar, food, nicotine, etc. The present invention further relates to the use of cortisol blockers (GR antagonists) for wound healing and transplants, the prevention or treatment of stress induced osteoporosis and the rapid healing of bone related injuries, and regenerative therapy.
    Type: Application
    Filed: December 15, 2014
    Publication date: April 16, 2015
    Inventors: Randice Lisa Altschul, Neil David Theise, Myron Rapkin, Rebecca O'Brien
  • Patent number: 9006223
    Abstract: Therapeutic compositions and methods for treatment of late-onset Gaucher disease are described herein. The compositions comprise compounds having activity as pharmacological chaperones for mutant forms of the beta-glucocerebrosidase. Methods of treatment involve providing therapeutically effective amounts of such compositions to subjects in need thereof.
    Type: Grant
    Filed: February 25, 2013
    Date of Patent: April 14, 2015
    Assignees: The Hospital for Sick Children, McMaster University
    Inventors: Don J Mahuran, Michael B Tropak, Justin D Buttner, Jan E Blanchard, Eric D Brown
  • Publication number: 20150086615
    Abstract: Novel sterol derivatives, the preparation method thereof, pharmaceutical compositions containing them and use thereof for treating diseases involving transformed astrocyte cells or for treating malignant haemopathies. The treatment of glioblastoma multiforme, as well as of other cancers, such as lymphomas, neuroblastomas and melanomas is also described.
    Type: Application
    Filed: May 7, 2013
    Publication date: March 26, 2015
    Applicant: BETA INNOV
    Inventors: Ludovic Clarion, Marcel Mersel, Didier Petite
  • Publication number: 20150071988
    Abstract: This invention comprises a sterically stabilized liposome carrier encapsulating a selected drug for the aerosol delivery of the drug effectual in the treatment of a mammal, a composition containing the sterically stabilized liposome carrier and a drug effective for the treatment a mammal as an aerosol and a method of treatment using the composition. The composition provides effective treatment for the longer of a period of time at least twice as long as the drug alone or up to at least one week.
    Type: Application
    Filed: August 6, 2014
    Publication date: March 12, 2015
    Inventors: Kameswari S. Konduri, Sandhya N. Nandedkar, Nejat Duzgunes, Pattisapu Ram Jogi Gangadharm
  • Publication number: 20150056279
    Abstract: The invention relates to tablet comprising granules dispersed in at least one hydrophilic compound or matrix. The granules contain an active agent, at least one amphiphilic compound and at least one lipophilic compound. The tablet may include a gastro-resistant film coating.
    Type: Application
    Filed: October 15, 2014
    Publication date: February 26, 2015
    Applicant: COSMO TECHNOLOGIES LIMITED
    Inventors: Roberto VILLA, Massimo PEDRANI, Mauro AJANI, Lorenzo FOSSATI
  • Patent number: 8951994
    Abstract: Therapeutic compositions and methods for treatment of late-onset Gaucher disease are described herein. The compositions comprise compounds having activity as pharmacological chaperones for mutant forms of the beta-glucocerebrosidase. Methods of treatment involve providing therapeutically effective amounts of such compositions to subjects in need thereof.
    Type: Grant
    Filed: November 14, 2012
    Date of Patent: February 10, 2015
    Assignees: The Hospital for Sick Children, McMaster University
    Inventors: Don J Mahuran, Michael B Tropak, Justin D Buttner, Jan E Blanchard, Eric D Brown
  • Patent number: 8945616
    Abstract: Embodiments of a controlled release minitablet comprise an extended release core and an optional pH dependent delayed release coating thereon, wherein the extended release core comprises budesonide, a carrier, and an extended release polymer. The budesonide may be embedded in the extended release polymer to facilitate extended release of the budesonide upon administration.
    Type: Grant
    Filed: February 17, 2009
    Date of Patent: February 3, 2015
    Assignee: Mylan Pharmaceuticals Inc.
    Inventors: Mummini Aruna Murty, Boyong Li
  • Patent number: 8945615
    Abstract: Embodiments of a controlled release minitablet comprise an extended release core and an optional pH dependent delayed release coating thereon, wherein the extended release core comprises budesonide, a carrier, an extended release polymer, and an acid. The budesonide may be embedded in the extended release polymer to facilitate extended release of the budesonide upon administration.
    Type: Grant
    Filed: February 17, 2009
    Date of Patent: February 3, 2015
    Assignee: Mylan Pharmaceuticals Inc.
    Inventors: Mummini Aruna Murty, Boyong Li
  • Publication number: 20150025050
    Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.
    Type: Application
    Filed: August 18, 2014
    Publication date: January 22, 2015
    Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
  • Patent number: 8937059
    Abstract: Therapeutic compositions and methods for treatment of late-onset Gaucher disease are described herein. The compositions comprise compounds having activity as pharmacological chaperones for mutant forms of the beta-glucocerebrosidase. Methods of treatment involve providing therapeutically effective amounts of such compositions to subjects in need thereof.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: January 20, 2015
    Assignees: The Hospital for Sick Children, McMaster University
    Inventors: Don J Mahuran, Michael B Tropak, Justin D Buttner, Jan E Blanchard, Eric D Brown
  • Publication number: 20150017103
    Abstract: The present invention relates to a waterless composition and foam as a vehicle in which an active pharmaceutical or cosmetic agent, when added is stable or stabilized by or its destabilization is impeded by the presence of a modulating agent. The pharmaceutical or cosmetic composition and foam, includes: a waterless solvent, a modulating agent and one or more active pharmaceutical or cosmetic agents. The present invention also relates to a method of treatment administering the waterless composition and foam.
    Type: Application
    Filed: October 3, 2013
    Publication date: January 15, 2015
    Applicant: Foamix Ltd.
    Inventors: Dov Tamarkin, Meir Eini, Doron Friedman, Tal Berman, David Schuz
  • Publication number: 20150017239
    Abstract: The present disclosure relates to methods for treating intestinal diseases presenting at least one inflammatory component such as inflammatory bowel disease or diverticular disease and/or maintaining remission of intestinal diseases presenting at least one inflammatory component such as inflammatory bowel disease (IBD) or diverticular disease using budesonide MMX compositions.
    Type: Application
    Filed: February 13, 2013
    Publication date: January 15, 2015
    Applicants: SANTARUS INC., COSMO TECHNOLOGIES LIMITED
    Inventors: Luigi Moro, Gerald Thomas Proehl, Wendell Wierenga, Michael Fangching Huang, Emerson David Ballard, II
  • Patent number: 8933062
    Abstract: The invention relates to nitrooxyderivative of corticosteroids of general formula (I) and pharmaceutically acceptable salts or stereoisomers thereof R—(Z)a—Rx??(I) wherein R is the corticosteroid residue of formula (II): wherein: R1 is OH, R2—CH3, or R1 and R2 are taken together to form a group of formula (III) R3 is Cl or F; R4 is H or F; wherein R1, R2, R3 and R4 can be linked to the correspondent carbon atoms of the steroidal structure in position ? or ?; with the proviso that: when R1 and R2 are the group of formula (III) then R3 is F and R4 is H or F; The compounds are useful in the treatment of respiratory diseases, inflammatory diseases, dermatological diseases and ocular diseases.
    Type: Grant
    Filed: January 28, 2008
    Date of Patent: January 13, 2015
    Assignee: Nicox S.A.
    Inventors: Francesca Benedini, Stefano Biondi, Ennio Ongini
  • Publication number: 20150010629
    Abstract: Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.
    Type: Application
    Filed: September 19, 2014
    Publication date: January 8, 2015
    Applicant: COSMO TECHNOLOGIES LIMITED
    Inventors: Roberto VILLA, Massimo PEDRANI, Mauro AJANI, Lorenzo FOSSATI
  • Publication number: 20150011518
    Abstract: A drug-dissolved non-aqueous liquid composition containing a drug, dioleylphosphatidylcholine, tocopherol and an organic solvent, wherein the blend concentration ratio between the dioleylphosphatidylcholine and the tocopherol falls within the range of 75/25 to 25/75, the blend concentration of the dioleylphosphatidylcholine falls within the range of 15 to 85% (w/w), the blend concentration of the tocopherol falls within the range of 15 to 85% (w/w), and the phase of the non-aqueous liquid composition changes into a non-lamellar liquid crystal upon contact with water, a phosphate buffer, a body fluid, a lacrimal fluid or a vitreous fluid.
    Type: Application
    Filed: January 30, 2013
    Publication date: January 8, 2015
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Kazuhito Yamada, Arto Urtti, Mechthild Burmester
  • Publication number: 20150005270
    Abstract: Provided herein are methods for treating, preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.
    Type: Application
    Filed: September 12, 2014
    Publication date: January 1, 2015
    Inventors: Elaine Phillips, Malcolm Hill
  • Publication number: 20140371179
    Abstract: Compositions and methods for treating esophageal diseases are disclosed. More specifically, these methods may refer to the treament of esophageal varices and eosinophilic esophagitis using an oral suspension drug for humans. The oral suspension drug may include poloxamer f127 used as vehicle and budesonide as a corticosteroid. Poloxamer oral suspension may be administrated by swallowing the poloxamer oral suspension drug which may slide down through the esophageal and may be adhered in the affected site providing a longer residence time. Additionally, poloxamer oral suspension may be mixed with APIs such as antifungals, antibacterials, and corticosteroids, previously dissolved in a suitable liquid, such as water.
    Type: Application
    Filed: June 13, 2013
    Publication date: December 18, 2014
    Applicant: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
    Inventor: Chris V. Simmons
  • Publication number: 20140370097
    Abstract: The present invention provides a method for the sterilization of a labile glucocorticosteroid, which method comprises heat-treating by moist heat the labile glucocorticosteroid in the form of a suspension for a sterilizing-effective time. The methods and compositions according to the invention are useful as therapeutic tools to prevent, reverse, and/or reduce the symptoms of allergic and/or inflammatory conditions in a mammalian patient. The invention also provides methods and compositions, which may be manipulated and fine-tuned to fit the condition(s) to be treated while producing fewer side effects.
    Type: Application
    Filed: June 20, 2014
    Publication date: December 18, 2014
    Inventors: Adrian Ashley, Paul Lamb, Donald MacDonald, John Miller, Martin J. Oliver, Mathew Pollard
  • Publication number: 20140363498
    Abstract: Some aspects of this disclosure relate to a method of treating an ophthalmic disease affecting an eye of a patient comprising forming a covalently-crosslinked hydrogel in situ at a peri-ocular, intra-ocular, or intra-vitreal site for controlled release of a therapeutic agent.
    Type: Application
    Filed: August 27, 2014
    Publication date: December 11, 2014
    Inventors: Amarpreet S. Sawhney, William H. Ransone, II
  • Patent number: 8906392
    Abstract: Compositions, methods of making, and methods of using nanoclusters in which the nanoclusters comprise a plurality of nanoparticles having a core of nanoparticles arranged such that the surfaces of the nanoparticles contact adjacent nanoparticles, the nanoparticles comprise an active ingredient, and the nanocluster has a mass median aerodynamic diameter of from about 0.25 ?m to about 20 ?m.
    Type: Grant
    Filed: November 24, 2010
    Date of Patent: December 9, 2014
    Assignee: University of Kansas
    Inventors: Cory J. Berkland, Lianjun Shi, Nashwa El Gendy, Carl Plumley, Mark Bailey
  • Publication number: 20140356438
    Abstract: Viscous formulations and methods of using such compositions, useful for intramuscular and intra-articular injection are provided to treat peripheral conditions. Such compositions can include triamcinolone particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 80,000 cps to about 300,000 cps. In a most preferred embodiment, the viscosity is in the range of from about 140,000 cps to about 280,000 cps at a shear rate of 0.1/second at 25° C. The compositions advantageously suspend the triamcinolone particles for prolonged periods of time.
    Type: Application
    Filed: August 19, 2014
    Publication date: December 4, 2014
    Inventors: Scott M. Whitcup, Michael R. Robinson, ROBERT T. LYONS, JOHN T. TROGDEN
  • Publication number: 20140356437
    Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.
    Type: Application
    Filed: August 18, 2014
    Publication date: December 4, 2014
    Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
  • Publication number: 20140357600
    Abstract: Described herein are compositions (e.g., a pharmaceutical composition) and methods for controlling the delivery of a therapeutic agent, and their use in the treatment and/or prevention of diseases and disorders.
    Type: Application
    Filed: June 6, 2014
    Publication date: December 4, 2014
    Applicant: CHEMIC LABORATORIES INC.
    Inventors: Joseph P. St. Laurent, Scott A. Goodrich, Gerald S. Jones, Jr.
  • Publication number: 20140357607
    Abstract: The present disclosure generally relates to pharmaceutical corticosteroid compositions, and methods of making the same.
    Type: Application
    Filed: June 3, 2014
    Publication date: December 4, 2014
    Inventors: Robert Lathrop, David Wade Osborne
  • Publication number: 20140349983
    Abstract: Provided herein are methods of treating and inducing ulcerative colitis in a subject. Also provided are methods of treating subjects with mild to moderate active ulcerative colitis, including ulcerative proctitis and proctosigmoiditis. Also provided are methods of administering budesonide to a subject to treat ulcerative colitis, including ulcerative proctitis and proctosigmoiditis.
    Type: Application
    Filed: July 31, 2014
    Publication date: November 27, 2014
    Inventors: William P. Forbes, Enoch Bortey, Craig Paterson, Pam Golden
  • Publication number: 20140348787
    Abstract: Compositions and methods for treating ear infections are disclosed. More specifically, these methods may refer to treatment of internal otitis using an otic composition, such as otic gel for animals and humans. Poloxamer otic gel may be in liquid state at room temperature and may change to gel at about temperature (64° F.) as poloxamer otic gel reaches body temperature, because of the thermo-reversible properties. Consequently, poloxamer otic gel may be an effective treatment in animals and humans, where poloxamer otic gel may reach otitis affected site and remain there for a longer period of time. Additionally, poloxamer otic gel may include APIs such as antifungals, antibiotics and corticosteroids, among others. Furthermore, poloxamer otic gel may be instilled inside the ear, employing calibrated delivery device into the vertical ear canal in order to reach the horizontal ear canal, without puncturing the tympanic membrane.
    Type: Application
    Filed: May 22, 2013
    Publication date: November 27, 2014
    Applicant: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
    Inventor: Chris V. Simmons
  • Publication number: 20140349982
    Abstract: Provided herein are methods of treating and inducing ulcerative colitis in a subject. Also provided are methods of treating subjects with mild to moderate active ulcerative colitis, including ulcerative proctitis and proctosigmoiditis. Also provided are methods of administering budesonide to a subject to treat ulcerative colitis, including ulcerative proctitis and proctosigmoiditis.
    Type: Application
    Filed: May 20, 2014
    Publication date: November 27, 2014
    Applicant: Salix Pharmaceuticals, Inc.
    Inventors: William Forbes, Enoch Bortey, Craig Paterson, Pam Golden
  • Publication number: 20140336161
    Abstract: The potency of a topical corticosteroid in a pharmaceutical formulation is maintained even when the concentration of the corticosteroid is substantially reduced by providing the corticosteroid in a formulation containing a liquid oil component that includes a dicarboxylic acid ester and/or a monocarboxylic acid ester.
    Type: Application
    Filed: July 24, 2014
    Publication date: November 13, 2014
    Inventors: Arturo Angel, Gordon Dow
  • Publication number: 20140336162
    Abstract: This invention provides for using a locally delivered low dose of a corticosteroid to treat pain caused by any inflammatory disease including sciatica, herniated disc, stenosis, mylopathy, low back pain, facet pain, osteoarthritis, rheumatoid arthritis, osteolysis, tendonitis, carpal tunnel syndrome, or tarsal tunnel syndrome. More specifically, a locally delivered low dose of a corticosteroid can be released into the epidural space, perineural space, or the foramenal space at or near the site of a patient's pain by a drug pump or a biodegradable drug depot.
    Type: Application
    Filed: July 28, 2014
    Publication date: November 13, 2014
    Inventors: William F. McKay, John Myers Zanella, Christopher M. Hobot
  • Publication number: 20140336160
    Abstract: This invention relates to novel glucocorticoid receptor agonists of formula (I): and to processes and intermediates for their preparation. The present invention also relates to pharmaceutical compositions containing these compounds, to their combination with one or more other therapeutic agents, as well as to their use for the treatment of a number of inflammatory and allergic diseases, disorders and conditions.
    Type: Application
    Filed: July 23, 2014
    Publication date: November 13, 2014
    Inventors: Paul Alan Glossop, David Simon Millan, David Anthony Price
  • Patent number: 8883768
    Abstract: Effective treatments for protecting against undesirable macrophage activity are provided. Through the administration of an effective amount of fluocinolone at or near a target site, one can reduce or prevent macrophage activity. In various embodiments, fluocinolone formulations may be provided within biodegradable polymers to prevent transplant rejection for at least thirty days. In some embodiments, the relief can be for at least sixty days, or up to ninety days.
    Type: Grant
    Filed: February 26, 2009
    Date of Patent: November 11, 2014
    Assignee: Warsaw Orthopedic, Inc.
    Inventor: Vanja Margareta King
  • Publication number: 20140323451
    Abstract: Described here are methods for the treatment of respiratory conditions using nebulized corticosteroids. The methods administer a dose of corticosteroid twice a day or more with nebulization times of 5 minutes or less. The faster nebulization times improve patient compliance. The methods also employ a lower corticosteroid dose while achieving therapeutic efficacy similar to commercially available formulations. This results in improved patient safety by reducing the systemic exposure of the corticosteroid.
    Type: Application
    Filed: July 8, 2014
    Publication date: October 30, 2014
    Inventors: STEPHEN B. SHREWSBURY, PAUL S. USTER, ANDREW P. BOSCO, THOMAS A. ARMER
  • Publication number: 20140302143
    Abstract: The invention relates to tablet comprising granules dispersed in at least one hydrophilic compound or matrix. The granules contain an active agent, at least one amphiphilic compound and at least one lipophilic compound. The tablet may include a gastro-resistant film coating.
    Type: Application
    Filed: June 18, 2014
    Publication date: October 9, 2014
    Applicant: COSMO TECHNOLOGIES LIMITED
    Inventors: Roberto VILLA, Massimo PEDRANI, Mauro AJANI, Lorenzo FOSSATI
  • Publication number: 20140302139
    Abstract: The invention relates to an oral pharmaceutical composition comprising an active agent, a macroscopically homogeneous structure and a gastro-resistant coating. The macroscopically homogeneous structure comprises at least one hydrophilic compound and at least one lipophilic compound and/or at least one amphiphilic compound. The macroscopically homogeneous structure controls the release of the active ingredient, and the gastro-resistant film prevents release of the active agent in the stomach.
    Type: Application
    Filed: June 18, 2014
    Publication date: October 9, 2014
    Applicant: COSMO TECHNOLOGIES LIMITED
    Inventors: Roberto VILLA, Massimo PEDRANI, Mauro AJANI, Lorenzo FOSSATI
  • Publication number: 20140296191
    Abstract: The present invention relates to pharmaceutical compositions of various pharmaceutical actives, especially lyophilic and hydrophilic actives containing Diethylene glycol monoethyl ether or other alkyl derivatives thereof as a primary vehicle and/or to pharmaceutical compositions utilizing Diethylene glycol monoethyl ether or other alkyl derivatives thereof as a primary vehicle or as a solvent system in preparation of such pharmaceutical compositions. The pharmaceutical compositions of the present invention are safe, non-toxic, exhibits enhanced physical stability compared to conventional formulations containing such pharmaceutical actives and are suitable for use as injectables for intravenous and intramuscular administration, as well as for use as a preformed solution/liquid for filling in and preparation of capsules, tablets, nasal sprays, gargles, dermal applications, gels, topicals, liquid oral dosage forms and other dosage forms.
    Type: Application
    Filed: April 2, 2014
    Publication date: October 2, 2014
    Applicant: THEMIS MEDICARE LIMITED
    Inventors: Dinesh Shantilal PATEL, Sachin Dinesh PATEL, Shashikant Prabhudas KURANI, Madhavlal Govindlal PATEL